UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours

Annals of oncology, 2007-03, Vol.18 (3), p.569-575

2007

Volltextzugriff (PDF)

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

British journal of cancer, 1997-01, Vol.76 (7), p.952-962

1997

Volltextzugriff (PDF)

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

European Journal of Cancer, 2009-07, Vol.45 (10), p.1764-1772

2009

Volltextzugriff (PDF)

Role of pharmacogenetics in irinotecan therapy

Cancer letters, 2006-03, Vol.234 (1), p.90-106

2006

Volltextzugriff (PDF)

Renal Toxicities of Chemotherapy

Seminars in oncology, 2006-02, Vol.33 (1), p.68-73

2006

Volltextzugriff (PDF)

Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients

Clinical cancer research, 2001-05, Vol.7 (5), p.1136-1141

2001

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-01, Vol.11 (2), p.703-711

2005

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

Anti-cancer drugs, 2013-02, Vol.24 (2), p.204-211

2013

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-05, Vol.11 (10), p.3806-3813

2005

Volltextzugriff (PDF)

Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations

Journal of clinical oncology, 2002-01, Vol.20 (1), p.81-87

Mathijssen, R. H.J.

2002

Volltextzugriff (PDF)

Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3733-3739

2001

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors

Journal of clinical oncology, 2001-02, Vol.19 (4), p.1167-1175

2001

Volltextzugriff (PDF)

Irinotecan (CPT-11) metabolism and disposition in cancer patients

Clinical cancer research, 1998-11, Vol.4 (11), p.2747-2754

1998

Volltextzugriff (PDF)

Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies

Clinical cancer research, 2000-09, Vol.6 (9), p.3451-3458

2000

Volltextzugriff (PDF)

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Clinical cancer research, 2003-09, Vol.9 (11), p.4101-4107

2003

Volltextzugriff (PDF)

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Clinical cancer research, 2005-02, Vol.11 (4), p.1504-1511

2005

Volltextzugriff (PDF)

The use of oral cytotoxic and cytostatic drugs in cancer treatment

European journal of cancer (1990), 2002-01, Vol.38 (1), p.18-22

2002

Volltextzugriff (PDF)

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

Annals of oncology, 2003-12, Vol.14 (12), p.1732-1734

2003

Volltextzugriff (PDF)

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

British journal of cancer, 2011-09, Vol.105 (7), p.938-944

2011

Volltextzugriff (PDF)

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Clinical cancer research, 2000-07, Vol.6 (7), p.2685-2689

2000

Volltextzugriff (PDF)

Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects

Journal of clinical oncology, 2000-05, Vol.18 (10), p.2104-2115

2000

Volltextzugriff (PDF)

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

European journal of cancer (1990), 2004-06, Vol.40 (9), p.1332-1334

2004

Volltextzugriff (PDF)

Achievements and future of chemotherapy

European Journal of Cancer, 2000-08, Vol.36 (12), p.1479-1487

2000

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1222-1231

Kehrer, D. F.S.

2002

Volltextzugriff (PDF)

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

Clinical cancer research, 2006-05, Vol.12 (9), p.2841-2848

2006

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(58)
Science & Technology
(58)
Humans
(55)
Oncology
(52)
Female
(42)
Biological And Medical Sciences
(40)
Medical Sciences
(40)
Aged
(38)
Male
(38)
Middle Aged
(38)
Pharmacology. Drug Treatments
(37)
Adult
(36)
Antineoplastic Agents
(34)
Chemotherapy
(33)
Neoplasms - Drug Therapy
(30)
Camptothecin - Analogs & Derivatives
(25)
Camptothecin - Pharmacokinetics
(17)
Antineoplastic Agents - Administration & Dosage
(16)
Antineoplastic Agents - Pharmacokinetics
(16)
Administration, Oral
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Role of pharmacogenetics in irinotecan therapy

Renal Toxicities of Chemotherapy

Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients

Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations

Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors

Irinotecan (CPT-11) metabolism and disposition in cancer patients

Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies

Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

The use of oral cytotoxic and cytostatic drugs in cancer treatment

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens

Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

Achievements and future of chemotherapy

Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

Suchergebnisse filtern